CA2464934A1 - Derives de pyrimido [4,5-b] indole - Google Patents

Derives de pyrimido [4,5-b] indole Download PDF

Info

Publication number
CA2464934A1
CA2464934A1 CA002464934A CA2464934A CA2464934A1 CA 2464934 A1 CA2464934 A1 CA 2464934A1 CA 002464934 A CA002464934 A CA 002464934A CA 2464934 A CA2464934 A CA 2464934A CA 2464934 A1 CA2464934 A1 CA 2464934A1
Authority
CA
Canada
Prior art keywords
pyrimido
indole
carbamoyl
amino
piperidinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002464934A
Other languages
English (en)
Inventor
Timothy Lowinger
Makoto Shimazaki
Hiroki Sato
Kazuho Tanaka
Naoki Tsuno
Karsten Marx
Masaru Yamamoto
Klaus Urbahns
Florian Gantner
Hiromi Okigami
Kosuke Nakashima
Keisuke Takeshita
Kevin B. Bacon
Hiroshi Komura
Nagahiro Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2001334662A external-priority patent/JP2003137886A/ja
Priority claimed from GB0214544A external-priority patent/GB2390090A/en
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of CA2464934A1 publication Critical patent/CA2464934A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention porte sur des pyrimido[4,5-b]indoles utiles en tant que principe actif de compositions pharmaceutiques. Les pyrimido[4,5-b]indoles de la présente invention ont une activité inhibitrice sur MKK7 et MKK4 et peuvent s'utiliser dans la prévention et le traitement des maladies associées à l'activité des MKK7 et MKK4. Ces maladies comprennent des troubles inflammatoires et immunorégulateurs et des maladies telles que l'asthme, la dermatite atopique, la rhinite, la rhinite allergique, les maladies allergiques, la BPCO, le choc septique, l'arthrite, les maladies des articulations et les accidents du myocarde ainsi que des pathologies auto-immunes telles que la polyarthrite rhumatoïde, la maladie de Graves et l'athérosclérose. Les composés de la présente invention sont aussi utiles dans le traitement de l'ischémie, de la lésion myocardique, de l'hypertension pulmonaire, de l'insuffisance rénale, de la chorée de Huntington et de l'hypertrophie cardiaque ainsi que de maladies neurodégénératives telles que la maladie de Parkinson, la maladie d'Alzheimer et l'ischémie focale.
CA002464934A 2001-10-31 2002-10-29 Derives de pyrimido [4,5-b] indole Abandoned CA2464934A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2001-334662 2001-10-31
JP2001334662A JP2003137886A (ja) 2001-10-31 2001-10-31 ピリミド［４，５−ｂ］インドール
GB0214544A GB2390090A (en) 2002-06-24 2002-06-24 Pharmaceutically active 6-carbamoylpyrimido[4,5-b]indoles
GB0214544.9 2002-06-24
PCT/EP2002/012057 WO2003037898A1 (fr) 2001-10-31 2002-10-29 Derives de pyrimido [4,5-b] indole

Publications (1)

Publication Number Publication Date
CA2464934A1 true CA2464934A1 (fr) 2003-05-08

Family

ID=26247088

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002464934A Abandoned CA2464934A1 (fr) 2001-10-31 2002-10-29 Derives de pyrimido [4,5-b] indole

Country Status (5)

Country Link
EP (1) EP1442039A1 (fr)
JP (1) JP2005515173A (fr)
CA (1) CA2464934A1 (fr)
MX (1) MXPA04004019A (fr)
WO (1) WO2003037898A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013110198A1 (fr) * 2012-01-27 2013-08-01 Université de Montréal Dérivés de pyrimido[4,5-b]indole et leur utilisation dans l'expansion des cellules souches hématopoïétiques

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2390090A (en) * 2002-06-24 2003-12-31 Bayer Ag Pharmaceutically active 6-carbamoylpyrimido[4,5-b]indoles
WO2004058764A1 (fr) * 2002-12-27 2004-07-15 Bayer Healthcare Ag Derives 4-phenyl-pyrimido [4,5-b]indoles
WO2006116733A2 (fr) * 2005-04-28 2006-11-02 Supergen, Inc. Inhibiteurs des proteines kinases
WO2009004329A1 (fr) * 2007-07-02 2009-01-08 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, et 9h-1,3,6,9-tétraaza-fluorènes en tant qu'inhibiteurs de la fonction kinase chk1
US7960400B2 (en) 2007-08-27 2011-06-14 Duquesne University Of The Holy Ghost Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
US7982035B2 (en) 2007-08-27 2011-07-19 Duquesne University Of The Holy Spirit Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
EP2247558B2 (fr) 2008-02-14 2024-07-03 Eli Lilly and Company Nouveaux agents d'imagerie pour la détection d'une dysfonction neurologique
AU2009329879A1 (en) 2008-12-23 2011-08-11 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
JP5699149B2 (ja) 2009-09-04 2015-04-08 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬
WO2012012712A2 (fr) * 2010-07-23 2012-01-26 President And Fellows Of Harvard College Composés renforçant l'activité protéasome tricyclique
US9045485B2 (en) 2010-12-16 2015-06-02 Convergence Pharmaceuticals Limited ASK 1 inhibiting pyrrolopyrimidine derivatives
CA2829939C (fr) 2011-03-15 2020-10-13 Trius Therapeutics, Inc. Inhibiteurs de la gyrase tricyclique
CA2849566C (fr) 2011-11-09 2021-02-09 Cancer Research Technology Limited Composes de type 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile et leur utilisation therapeutique
EP2806875B1 (fr) 2012-01-25 2017-07-19 Proteostasis Therapeutics, Inc. Composés permettant de moduler l'activité de protéasome
ES2624307T3 (es) 2012-05-15 2017-07-13 Cancer Research Technology Ltd 5-[[4-[[Morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]amino]pirazin-2-carbonitrilo y usos terapéuticos del mismo
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
CN104016985B (zh) * 2013-03-01 2017-11-03 华东理工大学 一种吡唑并嘧啶化合物及其用途
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
ES2788977T3 (es) * 2014-04-22 2020-10-23 Univ Montreal Compuestos y uso de los mismos en la expansión de células madre hematopoyéticas y/o células progenitoras hematopoyéticas
WO2016067009A1 (fr) * 2014-10-28 2016-05-06 Redx Pharma Plc Composés présentant une activité contre les bactéries et les mycobactéries
US10828329B2 (en) 2015-06-05 2020-11-10 Hema-Quebec Methods for culturing and/or differentiating hematopoietic stem cells into progenitors and uses thereof
RU2625316C1 (ru) * 2016-04-13 2017-07-13 Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) 2-АМИНОЗАМЕЩЕННЫЕ 6-МЕТОКСИ-4-ТРИФТОРМЕТИЛ-9Н-ПИРИМИДО[4,5b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ И ПРЕДШЕСТВЕННИКИ
SG11201900515PA (en) 2016-07-21 2019-02-27 Biogen Ma Inc Succinate forms and compositions of bruton's tyrosine kinase inhibitors
CN107353288B (zh) * 2017-06-23 2019-10-18 吉林大学 4-乙胺(2-羧基)-9H-嘧啶并[4,5-b]吲哚及其制备方法
CN111788195B (zh) 2018-01-31 2023-11-21 海帕瑞吉尼克斯股份有限公司 用于促进肝脏再生或减少或预防肝细胞死亡的蛋白激酶mkk4抑制剂
WO2019161494A1 (fr) 2018-02-20 2019-08-29 Universite De Montreal Expansion de cellules nk et dc in vivo médiant une réponse immunitaire
US11731968B2 (en) 2018-06-21 2023-08-22 Heparegenix Gmbh Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3104246A1 (fr) 2018-07-16 2020-01-23 Heparegenix Gmbh Inhibiteurs de proteine kinase permettant de favoriser la regeneration du foie, ou de reduire ou de prevenir la mort des hepatocytes
WO2020072675A1 (fr) 2018-10-02 2020-04-09 Northwestern University Bêta-carbolines servant de modulateurs allostériques positifs du récepteur humain de la sérotonine 2c (5-ht2c)
WO2021018820A1 (fr) * 2019-07-29 2021-02-04 Heparegenix Gmbh Inhibiteurs de protéine kinase de pyrazolo-pyridine substitués par hétéroaryle pour favoriser la régénération du foie ou réduire ou prévenir la mort des hépatocytes
US11945818B1 (en) 2023-09-06 2024-04-02 King Faisal University Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors
US11964981B1 (en) 2023-09-18 2024-04-23 King Faisal University Substituted pyrimido[4,5-b]indoles as CK2 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
JPH11501623A (ja) * 1995-03-02 1999-02-09 ファルマシア・アンド・アップジョン・カンパニー ピリミド［４，５−ｂ］インドール
PT964865E (pt) * 1997-01-08 2003-06-30 Upjohn Co Aminas triciclicas farmaceuticamente activas

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013110198A1 (fr) * 2012-01-27 2013-08-01 Université de Montréal Dérivés de pyrimido[4,5-b]indole et leur utilisation dans l'expansion des cellules souches hématopoïétiques
US20150011543A1 (en) * 2012-01-27 2015-01-08 Universite De Montreal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
US9409906B2 (en) 2012-01-27 2016-08-09 Universite De Montreal Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells
AU2013212457B2 (en) * 2012-01-27 2017-02-16 Universite De Montreal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
US10336747B2 (en) 2012-01-27 2019-07-02 Université de Montréal Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells

Also Published As

Publication number Publication date
EP1442039A1 (fr) 2004-08-04
JP2005515173A (ja) 2005-05-26
WO2003037898A1 (fr) 2003-05-08
MXPA04004019A (es) 2004-07-08

Similar Documents

Publication Publication Date Title
CA2464934A1 (fr) Derives de pyrimido [4,5-b] indole
US6329380B1 (en) SRC kinase inhibitor compounds
CA2551778C (fr) Derives d'acide imidazo[1,2-c]pyrimidinylacetique
EP1471057B1 (fr) Derivés de l'acid pyrimidinylacétique pour le traitment des maladies associées au CRTH2
CA2692859C (fr) Imidazopyrazines, pyrazolopyrazines et imidazotriazines et leur utilisation
US7745641B2 (en) Nitrogen-containing heterocyclic compound
AU2008273017B2 (en) Heterocyclic compounds useful as Raf kinase inhibitors
RU2493155C2 (ru) Замещенные пиримидины и их применение в качестве модуляторов jnk
JP6084291B2 (ja) Ｆｇｆｒ阻害剤の間歇投与用抗腫瘍剤
WO2004058764A1 (fr) Derives 4-phenyl-pyrimido [4,5-b]indoles
KR20070084066A (ko) 단백질 키나제 억제제 화합물 및 조성물
KR20110137838A (ko) Ａｋｔ 단백질 키나제 억제제
KR20110033239A (ko) 단백질 키나제 억제제
EP2552922A1 (fr) Pyrrolotriazines substituées à titre d'inhibiteurs de protéines kinases
AU2007293917A1 (en) Benzotriazole kinase modulators
AU2007264848A1 (en) Sulphur-containing cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
US20110212960A1 (en) New compounds for the treatment of cns disorder
Zhao et al. Discovery of novel Bruton’s tyrosine kinase (BTK) inhibitors bearing a pyrrolo [2, 3-d] pyrimidine scaffold
Yin et al. Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo [3, 4-d] pyrimidin-4-amino scaffold
CA2536535A1 (fr) Composes et compositions servant d'inhibiteurs de la proteine kinase
WO2023040537A1 (fr) Dérivé d'aminopyrimidine, son procédé de préparation et son utilisation
US20050070554A1 (en) Substituted heterocyclic compounds and methods of use
JP5570981B2 (ja) キナーゼ阻害剤としての縮合チアゾール誘導体
US7507834B2 (en) Substituted anilinopyrazoles
GB2390090A (en) Pharmaceutically active 6-carbamoylpyrimido[4,5-b]indoles

Legal Events

Date Code Title Description
FZDE Dead